Analysts Set Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Price Target at $6.64

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) have been given an average rating of "Hold" by the twelve research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $6.64.

Several equities research analysts have issued reports on the stock. Robert W. Baird lowered their price objective on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Craig Hallum decreased their price target on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Morgan Stanley dropped their price objective on Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Tuesday, March 25th. Baird R W lowered Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Finally, Stifel Nicolaus set a $5.00 target price on Maravai LifeSciences in a report on Friday, March 21st.

Maravai LifeSciences Trading Down 5.8%

MRVI stock traded down $0.13 during mid-day trading on Tuesday, reaching $2.13. 992,677 shares of the stock traded hands, compared to its average volume of 2,685,475. Maravai LifeSciences has a one year low of $1.66 and a one year high of $10.03. The stock has a market capitalization of $542.43 million, a PE ratio of -1.30 and a beta of 0.25. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74. The business has a 50-day moving average price of $2.07 and a two-hundred day moving average price of $3.55.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $46.85 million for the quarter, compared to the consensus estimate of $44.01 million. Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. The company's revenue for the quarter was down 26.9% on a year-over-year basis. Equities research analysts expect that Maravai LifeSciences will post -0.24 EPS for the current year.

Hedge Funds Weigh In On Maravai LifeSciences

A number of large investors have recently made changes to their positions in MRVI. Performa Ltd US LLC grew its stake in Maravai LifeSciences by 614.3% during the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company's stock worth $27,000 after buying an additional 4,300 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Maravai LifeSciences by 12.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 70,828 shares of the company's stock worth $387,000 after acquiring an additional 7,946 shares in the last quarter. VELA Investment Management LLC boosted its holdings in Maravai LifeSciences by 5.6% in the first quarter. VELA Investment Management LLC now owns 156,334 shares of the company's stock worth $345,000 after acquiring an additional 8,222 shares in the last quarter. Bleakley Financial Group LLC grew its stake in shares of Maravai LifeSciences by 30.1% during the fourth quarter. Bleakley Financial Group LLC now owns 41,691 shares of the company's stock worth $227,000 after acquiring an additional 9,657 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in shares of Maravai LifeSciences by 3,541.4% during the fourth quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company's stock valued at $56,000 after acquiring an additional 9,916 shares in the last quarter. 50.25% of the stock is owned by institutional investors and hedge funds.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.